Screener
Halozyme Therapeutics HALO Total Liabilities
Total Liabilities at other companies
Other financials
Where this comes from
Reported directly by Halozyme Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:Liabilities.
The source filing: Halozyme Therapeutics’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 4:11 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001159036-26-000104
FAQ
- What is Halozyme Therapeutics's total liabilities?
- Halozyme Therapeutics (HALO) reported total liabilities of $2.43B in Q2 2026.
- How has Halozyme Therapeutics's total liabilities changed year-over-year?
- Halozyme Therapeutics's total liabilities increased by 41.4% year-over-year, from $1.72B to $2.43B.
- What is the long-term trend for Halozyme Therapeutics's total liabilities?
- Over 3 years (2022 to 2025), Halozyme Therapeutics's total liabilities has grown at a 14.0% compound annual growth rate (CAGR), from $1.67B to $2.48B.
- What does total liabilities mean?
- The sum of all current and non-current obligations — everything the company owes to creditors, employees, governments, and other stakeholders.
Ask your AI about Halozyme Therapeutics's total liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude